FDA warns US Stem Cell Clinic of significant deviations
The U.S. Food and Drug Administration today posted a warning letter issued to US Stem Cell Clinic of Sunrise, Florida, and its Chief Scientific
Officer Kristin Comella for marketing stem cell products without FDA approval and for significant deviations from current good manufacturing practice
requirements, including some that could impact the sterility of their products, putting patients at risk.
